Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G; CARE-MS I and II Investigators.

Mult Scler. 2016 Nov 1:1352458516677589. doi: 10.1177/1352458516677589. [Epub ahead of print]

PMID:
27885061
2.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

3.

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, Hunter SF, Huffman C, Kim E, Pestreich L, McCague K, Barbato L; EPOC study investigators.

Mult Scler Relat Disord. 2014 Sep;3(5):607-19. doi: 10.1016/j.msard.2014.06.005. Epub 2014 Jul 4.

PMID:
26265273
4.
5.

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K.

BMC Neurol. 2014 Nov 26;14:220. doi: 10.1186/s12883-014-0220-1.

6.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
7.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

8.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
9.

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators.

Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74.

PMID:
19204263
10.

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators.

Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21.

PMID:
18208877
11.

Managing the symptoms of multiple sclerosis: a multimodal approach.

Crayton HJ, Rossman HS.

Clin Ther. 2006 Apr;28(4):445-60. Review.

PMID:
16750459
12.

A multimodal approach to managing the symptoms of multiple sclerosis.

Crayton H, Heyman RA, Rossman HS.

Neurology. 2004 Dec 14;63(11 Suppl 5):S12-8. Review.

PMID:
15596731
13.

The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis.

Wilken JA, Kane R, Sullivan CL, Wallin M, Usiskin JB, Quig ME, Simsarian J, Saunders C, Crayton H, Mandler R, Kerr D, Reeves D, Fuchs K, Manning C, Keller M.

Mult Scler. 2003 Mar;9(2):119-27.

PMID:
12708806
14.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN.

Arthritis Rheum. 2001 Dec;44(12):2862-9.

PMID:
11762947
15.

Spinal cord compression by epidural lipomatosis in a patient with systemic lupus erythematosus.

Crayton HE, Partington CR, Bell CL.

Arthritis Rheum. 1992 Apr;35(4):482-4. No abstract available.

PMID:
1567499
16.

Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.

Crayton H, Bohlmann T, Sufit R, Graziano FM.

Clin Exp Rheumatol. 1991 Sep-Oct;9(5):525-8.

PMID:
1954704
17.

Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis.

Crayton HE, Sundstrom WR.

Wis Med J. 1991 Apr;90(4):170-1.

PMID:
2042387
18.

Sacrococcygeal pain syndromes: diagnosis and treatment.

Traycoff RB, Crayton H, Dodson R.

Orthopedics. 1989 Oct;12(10):1373-7. Review.

PMID:
2678043

Supplemental Content

Loading ...
Support Center